2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025 PMID: 40795232, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilityComparing Claims Data to Stroke and Bleeding in the NCDR Left Atrial Appendage Occlusion Registry
Faridi K, Freeman J, Wang Y, Pereira L, Zimmerman S, Friedman D, Sharma R, Higgins A, Mortazavi B, Ross J, Krumholz H, Yeh R, Curtis J. Comparing Claims Data to Stroke and Bleeding in the NCDR Left Atrial Appendage Occlusion Registry. JACC Advances 2025, 4: 102019. PMID: 40712270, PMCID: PMC12311505, DOI: 10.1016/j.jacadv.2025.102019.Peer-Reviewed Original ResearchInternational ClassificationPositive predictive valueClaims dataRegistry dataIncidence rateNational Cardiovascular Data Registry LAAO RegistryGastrointestinal bleedingIntracranial hemorrhageHemorrhagic strokeBleeding eventsIschemic strokePostmarketing surveillanceTranscatheter left atrial appendage occlusionInpatient hospitalizationSurveillance of therapyRevision codesMajor bleeding eventsNegative predictive valueKappa statisticRegistryRegistry patientsModerate agreementEstimates of sensitivityMajor bleedingAppendage occlusion
2024
Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A)
Glaeser-Khan S, Richmond R, Ito S, Bona R, Krumholz H, Cuker A, Goshua G. Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A). Blood 2024, 144: 157-157. DOI: 10.1182/blood-2024-203690.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioStandard-of-careStandard half-lifeEmicizumab prophylaxisSevere hemophilia AIntracranial hemorrhageIntracranial hemorrhage incidenceSevere HAHemophilia AProbabilistic sensitivity analysesYears of agePrevention of intracranial hemorrhageNeurological disabilityPrevent intracranial hemorrhageIntracranial hemorrhage eventsIntracranial hemorrhage riskPhase III studyBase-casePersistent neurological disabilityAged 1 monthFactor VIII replacementStandard-of-care armUS societal perspectiveInfants Aged 0Aged 0
2009
Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention
Fazel R, Krumholz HM, Bates ER, French WJ, Frederick PD, Nallamothu BK. Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention. Circulation 2009, 120: 2455-2461. PMID: 19948977, DOI: 10.1161/circulationaha.109.860544.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionPCI-capable hospitalsPrimary PCIReperfusion strategyMyocardial infarctionFibrinolytic therapySystem-related factorsPercutaneous coronary intervention capabilityMyocardial Infarction (TIMI) risk scorePrimary percutaneous coronary interventionHierarchical multivariable logistic regressionKey clinical factorsPercutaneous coronary interventionMultivariable logistic regressionPCI useCardiogenic shockCoronary interventionClinical factorsIntracranial hemorrhageNonwhite raceNational registryRisk factorsAdvanced ageFemale gender
2005
The generalizability of observational data to elderly patients was dependent on the research question in a systematic review
Gross CP, Garg PP, Krumholz HM. The generalizability of observational data to elderly patients was dependent on the research question in a systematic review. Journal Of Clinical Epidemiology 2005, 58: 130-137. PMID: 15680745, DOI: 10.1016/j.jclinepi.2004.10.001.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectIntracranial hemorrhageSystematic reviewBeta-blocker useElderly patientsAngiography useCommunity patientsAtrial fibrillationRisk factorsObservational studyOutcome measuresRCT dataPresentation delayGlobal UtilizationT-PAPatientsSimilar predictorsTreatment variationStudy questionsCCP dataGUSTOHemorrhageReviewFibrillationAbsolute rate
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2000
Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction
Brass L, Lichtman J, Wang Y, Gurwitz J, Radford M, Krumholz H. Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction. Stroke 2000, 31: 1802-1811. PMID: 10926938, DOI: 10.1161/01.str.31.8.1802.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyIntracranial hemorrhageMyocardial infarctionElderly patientsIntracranial Hemorrhage AssociatedRetrospective cohort studyRisk stratification scaleMain outcome measuresAcute care hospitalsTissue plasminogen activatorExcessive anticoagulationPrior strokeCohort studyOlder patientsBlood pressureHemorrhage AssociatedIndependent predictorsMedical chartsSerious complicationsMedian weightAlternate therapyBlack racePrincipal diagnosisMedicare patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply